🟢 Generate Biomedicines is trading 5.6% up in pre-market with no confirmed company-specific catalyst

Generate Biomedicines is trading at $13.94, up +5.55%, as AI-enabled drug-discovery research draws attention; available sources do not confirm this news caused the pre-market gain.

• On October 27, Generate Biomedicines posted research describing Claude-assisted CAR T-cell receptor redesign; the company reported promising laboratory results, not patient outcomes.
• Anthropic also announced research partnerships with Generate and other drug developers, drawing attention to AI-enabled drug discovery.
• Prior coverage cited stronger biotech sentiment, without a confirmed company-specific catalyst.